Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
90 Leser
Artikel bewerten:
(0)

Active-Investors: Blog Exposure - NovoCure Announced Positive Top-line Results from STELLAR Trial Assessing TTFields in Mesothelioma

Stock Monitor: Neovasc Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on NovoCure Ltd (NASDAQ: NVCR). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=NVCR as the Company's latest news hit the wire. On April 17, 2018, the Company announced positive top-line results from its phase-2 pilot trial, STELLAR, evaluating Tumor Treating Fields (TTFields) plus standard of care chemotherapy, pemetrexed and cisplatin or carboplatin, in patients with mesothelioma, compared to historical control data of patients who received standard of care chemotherapy alone. The data demonstrated clinically meaningful improvements in overall survival (OS) and progression free survival (PFS). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Neovasc Inc. (NASDAQ: NVCN), which also belongs to the Healthcare sector as the Company NovoCure. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/'symbol=NVCN

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, NovoCure most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/'symbol=NVCR

Final Data of STELLAR Phase-2 Trial Exceeded the Results of Interim Analysis

The STELLAR trial is a phase-2 pilot single-arm, open-label, multi-center trial designed to test the efficacy and safety of TTFields in combination with standard of care chemotherapy, pemetrexed combined with cisplatin or carboplatin, in 80 patients with unresectable, previously untreated malignant pleural mesothelioma. An interim analysis of the first 42 patients enrolled in the trial with an average follow-up time of 11.5 months was presented at the International Association for the Study of Lung Cancer (IASLC) in December 2016. The one-year survival rate of patients treated with TTFields combined with pemetrexed and cisplatin or carboplatin was 80%. Median PFS in the TTFields-treated group was 7.3 months and one-year survival rate was 79.7%.

The final data exceeded the results of the interim analysis for all efficacy endpoints. No device-related serious adverse events were reported. NovoCure will submit the full data for presentation at an upcoming medical conference.

Mesothelioma is the First Torso Indication for which NovoCure Will Pursue FDA Approval

Dr. Eilon Kirson, Chief Science Officer and Head of Research and Development at NovoCure, stated that the Company is extremely pleased with these top-line results, which brings it one step closer to realizing the potential for a new treatment for mesothelioma patients in desperate need. According to him, Mesothelioma is the first torso indication for which NovoCure will pursue FDA approval.

Dr. Eilon added that the STELLAR data reinforce NovoCure's belief that TTFields may be a broadly applicable platform technology for the treatment of solid tumors.

NovoCure Plans to Submit a Humanitarian Device Exemption Application to the FDA

In May 2017, NovoCure received Humanitarian Use Device (HUD) designation for the use of TTFields for the treatment of pleural mesothelioma. Based upon the final STELLAR data, the Company plans to submit a Humanitarian Device Exemption (HDE) application to the FDA for approval. An approved HDE would allow NovoCure to market TTFields in combination with standard of care chemotherapy as a treatment for pleural mesothelioma in the United States.

About Mesothelioma

Mesothelioma is a rare, aggressive form of cancer that develops in the lining of the lungs, abdomen, or heart. Caused by asbestos, mesothelioma has no known cure and has a very poor prognosis. According to a 2017 report by the Centers for Disease Control, 2,400-2,800 people are diagnosed with mesothelioma in the United States each year.

About NovoCure Ltd

Founded in 2000 and headquartered in Saint Helier, Jersey, NovoCure is a commercial-stage oncology company developing a novel, proprietary therapy called TTFields, for the treatment of solid tumor cancers. NovoCure's commercialized product is approved for the treatment of adult patients with glioblastoma.

Stock Performance Snapshot

April 18, 2018 - At Wednesday's closing bell, NovoCure's stock climbed 2.37%, ending the trading session at $23.80.

Volume traded for the day: 2.38 million shares, which was above the 3-month average volume of 871.02 thousand shares.

Stock performance in the last month - up 10.70%; previous three-month period - up 14.70%; past twelve-month period - up 120.37%; and year-to-date - up 17.82%

After yesterday's close, NovoCure's market cap was at $2.17 billion.

The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry. This sector was flat at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2018 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.